Governments and public institutions must evaluate the effectiveness of public policies and assess their impact on social welfare in order to determine how to improve their interventions and identify in which areas these are most effective. This work requires:
We master empirical techniques and analytical tools necessary to assess with precision whether a specific policy is having its intended effect on the economy and to evaluate the size of this impact, to gauge its costs and benefits, and to determine how to improve it.
Relevant projects include: a project for the DG Economic and Financial Affairs of the European Commission aimed at developing an empirical methodology for the evaluation of the effectiveness of different competition policy regimes around the world in deterring anticompetitive behavior and fostering productivity. We have also designed a procedure for the ex-post review of merger control decisions to help the DG Competition of the European Commission to improve its enforcement policy and we have assessed the cost of erroneous antitrust decisions under Article 102 for the UK Office of Fair Trading.
If you need advice in the evaluation of any matter related to policy intervention, contact us.
Lear has been appointed by the World Bank Group to build and deliver a database encompassing information on key policy dimensions regarding State-owned enterprises (“SOEs”) in 20 countries for 22 sectors, including input and manufacturing sectors, in each of the selected countries. Such information is key to understand and identify the role of SOEs in […] Read more
Lear is supporting one of Italy’s leading airport operators in the preparation of its position paper in the public consultation issued by the Italian Transport Regulator on the revision of regulatory models for airport charges. Lear’s contribution is aimed at providing a reconstruction of the competitive dynamics prevailing in the markets where airports operate and […] Read more
Lear has been appointed by the European Commission to carry out an ex-post evaluation of EU competition enforcement looking at acquisitions of innovative competitors in the pharmaceutical sector that have led to the discontinuation of overlapping drug research and development projects to the detriment of future competition (“killer acquisitions”).